Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00976989
Registration number
NCT00976989
Ethics application status
Date submitted
14/09/2009
Date registered
15/09/2009
Date last updated
6/02/2017
Titles & IDs
Public title
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
Query!
Scientific title
A Randomised, Multicentre, Multinational Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab, Given Either Concomitantly or Sequentially With Standard Anthracycline-based Chemotherapy or Concomitantly With a Non-anthracycline-based Chemotherapy Regimen, as Neoadjuvant Therapy for Patients With Locally Advanced, Inflammatory or Early Stage HER2-positive Breast Cancer
Query!
Secondary ID [1]
0
0
2009-012019-17
Query!
Secondary ID [2]
0
0
BO22280
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Pertuzumab
Treatment: Drugs - Trastuzumab
Treatment: Drugs - FEC
Treatment: Drugs - Docetaxel
Treatment: Drugs - TCH
Experimental: T+P Concomitant Anthracycline-based chemotherapy - 5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab (T) and pertuzumab (P) every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
Experimental: T+P Sequential Anthracycline-based chemotherapy - FEC every three weeks for three cycles, followed by docetaxel, trastuzumab (T) and pertuzumab (P) every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
Experimental: T+P Concomitant Non-Anthracycline chemotherapy - Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab (P) every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
Treatment: Drugs: Pertuzumab
840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
Treatment: Drugs: Trastuzumab
8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
Treatment: Drugs: FEC
5-fluorouracil 500 mg/m^2, epirubicin 100 mg/m^2 and cyclophosphamide 600 mg/m^2.
Treatment: Drugs: Docetaxel
75 mg/m^2 for the first dose; 100 mg/m^2 if no dose limiting toxicity occurs.
Treatment: Drugs: TCH
Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m^2. All treatments were given every three weeks by the IV route.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety: Percentage of Participants With Symptomatic Cardiac Events as Assessed by the Investigator
Query!
Assessment method [1]
0
0
Left ventricular systolic dysfunction (LVSD) as assessed by the Investigator, including Grade 3, 4 or 5 symptomatic LVSD with symptomatic cardiac events.
Query!
Timepoint [1]
0
0
From baseline up to approximately 3.5 years
Query!
Primary outcome [2]
0
0
Safety: Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Decline During Pre-operative (Neoadjuvant) Period
Query!
Assessment method [2]
0
0
Percentage of participants with LVEF measures decline of = 10% from baseline and to a value of <50% during the pre-operative (neoadjuvant) period.
Query!
Timepoint [2]
0
0
From baseline up to approximately 18 weeks
Query!
Secondary outcome [1]
0
0
Efficacy: Percentage of Participants With Complete Pathological Response (pCR)
Query!
Assessment method [1]
0
0
pCR is defined as the absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. pCR is evaluated after 6 cycles of treatment and surgery or following withdrawal from the study whichever occurs sooner.
Query!
Timepoint [1]
0
0
At surgery, after 18 weeks (6 cycles) of treatment
Query!
Secondary outcome [2]
0
0
Efficacy: Clinical Response Rate
Query!
Assessment method [2]
0
0
Tumor response is defined as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) and is identified as per local practice. Clinical response rate is defined as the percentage of participants who achieve a response of CR or PR at any time pre-surgery. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by mammogram or magnetic resonance imaging (MRI) and clinical breast examination (CBE), CR is disappearance of all target lesions; PR is >=30% decrease in the sum of the longest diameter of target lesions.
Query!
Timepoint [2]
0
0
During each 3-week cycle of 6 total cycles: up to 18 weeks
Query!
Secondary outcome [3]
0
0
Efficacy: Time to Clinical Response
Query!
Assessment method [3]
0
0
Time to clinical response is defined as the time from the date of first dose received to the first date of assessment of clinical response. Clinical response is defined as a response of CR or PR at any time pre-surgery. Per RECIST v1.0 for target lesions and assessed by mammogram or MRI and CBE, CR is disappearance of all target lesions; PR is >=30% decrease in the sum of the longest diameter of target lesions.
Query!
Timepoint [3]
0
0
Up to 18 weeks
Query!
Secondary outcome [4]
0
0
Efficacy: Percentage of Participants Achieving Breast Conserving Surgery
Query!
Assessment method [4]
0
0
This is the percentage of participants who achieved breast conserving surgery out of the intent-to-treat population without inflammatory breast cancer, as these participants received mastectomy irrespective of their response to neoadjuvant (pre-operative) treatment.
Query!
Timepoint [4]
0
0
At approximately 18 weeks
Query!
Secondary outcome [5]
0
0
Efficacy: Percentage of Participants Without an Overall Survival (OS) Event
Query!
Assessment method [5]
0
0
Overall survival (OS) was defined as the time from randomization to the date of death from any cause. Participants who were alive or lost to follow-up were censored at the last known alive date. Participants with no post-baseline information were censored at the date of randomization plus one day.
Query!
Timepoint [5]
0
0
From baseline to end of study up to 5 years
Query!
Secondary outcome [6]
0
0
Efficacy: Percentage of Participants Without a Disease-Free Survival (DFS) Event
Query!
Assessment method [6]
0
0
The DFS was defined as the time from the first date of no disease (i.e., date of surgery) to the first documentation of progressive disease (PD) or death. PD was assessed using RECIST v1.0 and MRI and CBE. It was defined as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions. Any evidence of contralateral disease in situ was not considered as PD. Participants who were withdrawn from the study without documented PD were censored at the date of the last assessment when the participant was known to be disease-free.
Query!
Timepoint [6]
0
0
From baseline to end of study up to 5 years
Query!
Secondary outcome [7]
0
0
Efficacy: Percentage of Participants Without a Progression-Free Survival (PFS) Event
Query!
Assessment method [7]
0
0
Progression-free survival was defined as the time from the date of randomization to the first documentation of PD or death from any cause, whichever occurred first. PD was assessed using RECIST v1.0 and MRI and CBE. It was defined as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions. Participants who were withdrawn from the study without documented PD were censored at the date of the last assessment when the participant was known to be free from PD. Participants without post-baseline assessments but known to be alive were censored at the time of randomization plus one day.
Query!
Timepoint [7]
0
0
From baseline to end of study up to 5 years
Query!
Secondary outcome [8]
0
0
Safety: Percentage of Participants With Cardiac Symptoms Associated With Symptomatic Left Ventricular Systolic Dysfunction (LVSD)
Query!
Assessment method [8]
0
0
Percentage of participants with signs or symptoms of cardiac events.
Query!
Timepoint [8]
0
0
From Baseline to end of Neoadjuvant Period (up to 18 weeks), Adjuvant Period (up to 1.5 years), Follow-up Period (up to 3.5 years)
Query!
Secondary outcome [9]
0
0
Safety: Percentage of Participants With Asymptomatic Left Ventricular Ejection Fraction (LVEF) Events
Query!
Assessment method [9]
0
0
Percentage of participants with LVEF events without signs or symptoms of cardiac events.
Query!
Timepoint [9]
0
0
From baseline to end of Neoadjuvant Period (up to 18 weeks), Adjuvant Period (up to 1.5 years), Follow-up Period (up to 3.5 years)
Query!
Secondary outcome [10]
0
0
Safety: Maximum Decrease in Left Ventricular Ejection Fraction (LVEF) Measures
Query!
Assessment method [10]
0
0
Maximum decrease in LVEF measures is the change from baseline at worst treatment value. LVEF is measured as percentage.
Query!
Timepoint [10]
0
0
From baseline up to approximately 3.5 years
Query!
Eligibility
Key inclusion criteria
- female participants, age >/=18 years
- advanced, inflammatory or early stage unilateral invasive breast cancer
- HER2-positive breast cancer
- baseline left ventricular ejection fraction (LVEF) >/=55%
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- metastatic disease (Stage IV) or bilateral breast cancer
- previous anticancer therapy or radiotherapy for any malignancy
- other malignancy, except for carcinoma in situ of the cervix, or basal cell carcinoma
- clinically relevant cardiovascular disease
- current chronic treatment with corticosteroids of >10mg methylprednisolone or
equivalent
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/01/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
225
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Bahamas
Query!
State/province [1]
0
0
Nassau
Query!
Country [2]
0
0
Bosnia and Herzegovina
Query!
State/province [2]
0
0
Banja Luka
Query!
Country [3]
0
0
Bosnia and Herzegovina
Query!
State/province [3]
0
0
Sarajevo
Query!
Country [4]
0
0
Brazil
Query!
State/province [4]
0
0
RS
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
SP
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
British Columbia
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Ontario
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
Quebec
Query!
Country [9]
0
0
Croatia
Query!
State/province [9]
0
0
Pula
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Heidelberg
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Kiel
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Regensburg
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Trier
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Troisdorf
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Ulm
Query!
Country [16]
0
0
Greece
Query!
State/province [16]
0
0
Heraklion
Query!
Country [17]
0
0
Greece
Query!
State/province [17]
0
0
Thessaloniki
Query!
Country [18]
0
0
Italy
Query!
State/province [18]
0
0
Lazio
Query!
Country [19]
0
0
Italy
Query!
State/province [19]
0
0
Lombardia
Query!
Country [20]
0
0
Korea, Republic of
Query!
State/province [20]
0
0
Daegu
Query!
Country [21]
0
0
Korea, Republic of
Query!
State/province [21]
0
0
Seoul
Query!
Country [22]
0
0
Mexico
Query!
State/province [22]
0
0
Mexico City
Query!
Country [23]
0
0
Mexico
Query!
State/province [23]
0
0
Xalapa
Query!
Country [24]
0
0
New Zealand
Query!
State/province [24]
0
0
Auckland
Query!
Country [25]
0
0
Portugal
Query!
State/province [25]
0
0
Aveiro
Query!
Country [26]
0
0
Portugal
Query!
State/province [26]
0
0
Lisboa
Query!
Country [27]
0
0
Romania
Query!
State/province [27]
0
0
Bucharest
Query!
Country [28]
0
0
Romania
Query!
State/province [28]
0
0
Cluj Napoca
Query!
Country [29]
0
0
Romania
Query!
State/province [29]
0
0
Iasi
Query!
Country [30]
0
0
Serbia
Query!
State/province [30]
0
0
Belgrade
Query!
Country [31]
0
0
South Africa
Query!
State/province [31]
0
0
Durban
Query!
Country [32]
0
0
South Africa
Query!
State/province [32]
0
0
Pretoria
Query!
Country [33]
0
0
Spain
Query!
State/province [33]
0
0
Guipuzcoa
Query!
Country [34]
0
0
Spain
Query!
State/province [34]
0
0
Barcelona
Query!
Country [35]
0
0
Spain
Query!
State/province [35]
0
0
Cordoba
Query!
Country [36]
0
0
Spain
Query!
State/province [36]
0
0
Madrid
Query!
Country [37]
0
0
Sweden
Query!
State/province [37]
0
0
Eskilstuna
Query!
Country [38]
0
0
Sweden
Query!
State/province [38]
0
0
Stockholm
Query!
Country [39]
0
0
Sweden
Query!
State/province [39]
0
0
Sundsvall
Query!
Country [40]
0
0
Sweden
Query!
State/province [40]
0
0
Umea
Query!
Country [41]
0
0
Switzerland
Query!
State/province [41]
0
0
Baden
Query!
Country [42]
0
0
Switzerland
Query!
State/province [42]
0
0
Zürich
Query!
Country [43]
0
0
Taiwan
Query!
State/province [43]
0
0
Taichung
Query!
Country [44]
0
0
Taiwan
Query!
State/province [44]
0
0
Taipei
Query!
Country [45]
0
0
United Kingdom
Query!
State/province [45]
0
0
Bournemouth
Query!
Country [46]
0
0
United Kingdom
Query!
State/province [46]
0
0
Derby
Query!
Country [47]
0
0
United Kingdom
Query!
State/province [47]
0
0
Guildford
Query!
Country [48]
0
0
United Kingdom
Query!
State/province [48]
0
0
Newcastle Upon Tyne
Query!
Country [49]
0
0
United Kingdom
Query!
State/province [49]
0
0
Southampton
Query!
Country [50]
0
0
United Kingdom
Query!
State/province [50]
0
0
Truro
Query!
Country [51]
0
0
United Kingdom
Query!
State/province [51]
0
0
Westcliffe-on-sea
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This 3 arm study will assess the tolerability, safety and efficacy of 3 neoadjuvant treatment
regimens in participants with locally advanced, inflammatory or early stage human epidermal
growth factor receptor 2 (HER2)-positive breast cancer. Before surgery, participants will be
randomized to receive either A) 6 cycles of pertuzumab plus trastuzumab (Herceptin), with
5-fluorouracil/epirubicin/cyclophosphamide (FEC) for cycles 1-3 and docetaxel for cycles 4-6,
or B) FEC for cycles 1-3 followed by pertuzumab plus trastuzumab with docetaxel for cycles
4-6, or C) 6 cycles of pertuzumab plus trastuzumab with docetaxel and carboplatin. Pertuzumab
will be administered at a loading dose of 840 mg intravenously (iv), then 420 mg iv 3-weekly,
trastuzumab at a loading dose of 8 mg/kg iv, then 6 mg/kg iv 3-weekly, docetaxel at 75 mg/m^2
iv, increased to 100 mg/m^2 iv 3-weekly, and FEC and carboplatin iv 3-weekly at standard
doses. Following surgery participants will receive trastuzumab 6 mg/kg iv 3-weekly for a
total of 1 year, as well as adequate chemo-, radio- and hormone therapy. Anticipated time on
study treatment is 4-12 months, and target sample size is 200-300.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00976989
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00976989
Download to PDF